Measurement of Outcome of Surgical Treatment in Patients With Acromegaly
- Conditions
- Acromegaly
- Registration Number
- NCT00005100
- Lead Sponsor
- National Center for Research Resources (NCRR)
- Brief Summary
OBJECTIVES: I. Compare growth hormone (GH) levels at baseline and after glucose suppression measured with both a polyclonal radioimmunoassay and a highly sensitive immunoradiometric assay (IRMA) in patients with acromegaly and normal volunteers.
II. Measure the levels of IGF-I and its binding protein, IGFBP-3, in these cohorts.
III. Determine any correlation between levels of IGF-I and IGFBP-3 and GH suppressibility as assessed by sensitive IRMA.
IV. Determine if patients who demonstrate biochemical features of mild GH excess are at risk for progression to active disease.
- Detailed Description
PROTOCOL OUTLINE: Blood samples are collected and assessed for growth hormone and IGF-I by polyclonal radioimmunoassay (RIA) and immunoradiometric assay (IRMA). Growth hormone is measured at baseline and 60, 90, and 120 minutes after a 100 g glucose drink. Serum glucose is measured at baseline and at 2 hours post dextrose administration by the glucose hexokinase method.
Clinical scores are determined for headache, perspiration, fatigue, joint pain, and acne.
Exams and tests may be repeated every 6 months for 2 years.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 165
Not provided
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Columbia University College of Physicians and Surgeons
🇺🇸New York, New York, United States